Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O43520

UPID:
AT8B1_HUMAN

ALTERNATIVE NAMES:
ATPase class I type 8B member 1; Familial intrahepatic cholestasis type 1; P4-ATPase flippase complex alpha subunit ATP8B1

ALTERNATIVE UPACC:
O43520; Q9BTP8

BACKGROUND:
ATP8B1, known for its pivotal role in the establishment of canalicular membrane integrity, is involved in the regulation of bile acids transport. It ensures the asymmetric distribution of phospholipids in the canicular membrane, protecting hepatocytes from bile salts. ATP8B1's function extends beyond its flippase activity, contributing to microvillus formation and apical membrane localization of key proteins.

THERAPEUTIC SIGNIFICANCE:
Variants affecting ATP8B1 are linked to liver diseases such as progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis, and intrahepatic cholestasis of pregnancy. Targeting ATP8B1's pathway offers a promising avenue for developing treatments for these debilitating liver conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.